Navigation Links
Anti-estrogen combo better than single drug for hormone-sensitive breast cancer
Date:12/7/2011

ANN ARBOR, MICH. Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

The combination of the two anti-estrogen drugs anastrozole and fulvestrant used in the SWOG S0226 trial extended the median survival time of women with breast cancer by more than six months compared to those who underwent standard treatment with anastrozole alone (47.7 months vs 41.3 months). The combination therapy also lengthened the median time to disease progression (15 months vs 13.5 months).

Lead study coordinator Rita Mehta, M.D., of the University of California, Irvine Medical Center says the results of the phase III trial are particularly exciting because "these patients have not had a new treatment that gave them an overall survival benefit in more than a decade."

Anastrozole (Arimidex) and fulvestrant (Faslodex) are both already used in treating breast cancer, though not in combination. The former reduces the production of tumor-promoting estrogen, while the latter interferes with the receptors that allow estrogen to signal cells to grow and reproduce.

Researchers think it's these two different modes of action together that make the combination so effective against hormone receptor-positive breast cancer, the subtype that accounts for more than half of all breast cancers.

"If we take away estrogen and the estrogen receptor, the two together should be better than just doing one at a time," says Mehta.

Starting in the spring of 2004, she and colleagues at 72 other institutions enrolled 707 postmenopausal women with metastatic hormone receptor-positive breast cancer to the trial.

Women were assigned at random to one of the study's two arms. Patients on both arms got a standard 1 mg oral daily dose of anastrozole. Those on the combination arm also got a 250 mg injection of fulvestrant every 28 days, after an initial set of injections to raise the level of fulvestrant in their bloodstream. Researchers saw no significant differences in how well patients tolerated the two therapies.

The overall survival benefit was particularly strong in women who had not previously had tamoxifen therapy for their breast cancer. Among this tamoxifen-naive group (about 60 percent of patients in each arm), median overall survival time on the combination therapy was 47.7 months as compared to 39.7 months for those taking only anastrozole.

The trial researchers are hesitant, however, to focus too much attention on this aspect of the findings. Because plans to analyze the results by prior tamoxifen use were not built into the original trial design, the results of that analysis must clear a higher bar to be found statistically significant.

"We need to better understand other possible factors, since the prior tamoxifen factor could be a false lead from an unplanned analysis," says Mehta, who is eager to see whether even more patients might benefit from this combination treatment.

"The next step for researchers," she says, "would be to try the combination in even earlier stages of breast cancer to test whether long-term cures could be increased at those stages."


'/>"/>
Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Anti-estrogen medication reduces risk of dying from lung cancer
2. Tender Breasts From Combo HRT Linked to Higher Cancer Risk
3. Combo hormone therapy has increased breast cancer risk over estrogen alone
4. New drug combo targets multiple cancers
5. Breast tenderness in women getting combo hormone therapy associated with increase in breast density
6. FDA Approves First Combo Drug for Diabetes, Cholesterol
7. Drug Combo Might Fight Aggressive Breast Cancer More Safely
8. For Some Prostate Cancer Patients, Combo Treatment Improves Survival
9. New Combo Therapy May Prevent TB, Save Lives in People With HIV
10. Vitamin D, Calcium Combo May Halve Melanoma Risk in Some Women
11. Energy Drink-Vodka Combo Nearly Kills Teen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... Petaluma, CA (PRWEB) , ... August 16, 2017 ... ... donate and distribute $100,000 in AED (Automated External Defibrillator) machines to their local ... an AED device from Arrow Benefits Group. AED machines are an integral part ...
(Date:8/16/2017)... ... ... of A Child” is the creation of published author, Pauline DiBenedetto. , “As my mother ... was in such great pain, my mother thought that her time has come. Once I ... I was about eight years old, when I had a vision of my own, that ...
(Date:8/15/2017)... Los Angeles, CA (PRWEB) , ... August 15, 2017 , ... The city of Los ... styles exist in harmony with “Cali Style”. LA’s Top Style List, a website that spotlights ... to help the public wear their wardrobe all year long. , According to the senior ...
(Date:8/15/2017)... ... August 15, 2017 , ... The V Foundation ... 19th Annual V Foundation Wine Celebration raised nearly $9 million for cancer research ... million in “Fund-A-Need” donations to support the study of BRCA mutation research in ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
(Date:7/26/2017)... Fla. , July 26, 2017 Sancilio ... enrollment of our clinical trial evaluating Altemia TM , ... Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT ... evaluate the efficacy and safety of Altemia TM ... is conducted under US IND 125274. ...
(Date:7/24/2017)... N.Y. , July 24, 2017 IBM (NYSE: ... the Gartner Magic Quadrant for Solid-State Arrays (SSA) for the ... According to Gartner, "Vendors in the Leaders ... and Completeness of Vision. A vendor in the Leaders quadrant ... needed to drive the acceptance of new technologies. These vendors ...
Breaking Medicine Technology: